Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2019-05-15 Annual Report
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
20-F/A
Annual Report FY 2018
2019-05-15 English
Regulatory Filings 2019
Regulatory Filings
2019-05-09 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. The content primarily consists of a Notice of Annual General Meeting (AGM) of Shareholders, detailing the date, location, agenda items including board elections, auditor appointments, amendments to articles of association, compensation policies, and option grants. It also includes procedural details about voting rights, proxy submission, and shareholder participation. There is no substantive financial data or detailed financial statements included, only a notice and agenda for the upcoming AGM. The document is not a full annual report, earnings release, or management discussion, but rather a formal notification of the AGM and its agenda. Therefore, the document fits the category of AGM Information (AGM-R). The document length (9646 characters) supports that it is a detailed notice rather than a brief announcement or a full report.
2019-05-09 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release reporting first quarter 2019 financial results and business highlights, as well as condensed consolidated interim unaudited financial information for the quarter ended March 31, 2019. Form 6-K filings are used by foreign private issuers to report material information between annual reports. The presence of interim financial data and the quarterly period indicates this is an interim or quarterly report. The document length is 2204 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2019-05-07 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release about submitting a new drug application. The document is relatively short (2025 characters) and primarily serves as an announcement of a press release rather than a detailed financial or operational report. Form 6-K filings are typically periodic reports for foreign issuers and often contain regulatory announcements or press releases. Given the nature and length, this fits best under Regulatory Filings (RNS) as it does not contain detailed financial statements or comprehensive report content but is a regulatory announcement filing.
2019-05-07 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It references a press release about hosting a first quarter 2019 financial results conference call. The document is short (2039 characters) and primarily serves as a notification of the press release and upcoming call, not containing actual financial statements or detailed financial analysis. It does not contain the full transcript or detailed financial report itself. According to the rules, such a filing is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Earnings Release or Call Transcript. Therefore, the classification is RNS with high confidence.
2019-04-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.